Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Iseganan: IBPI completed enrollment of 509 patients in its U.S. Phase III trial of iseganan to reduce the incidence and severity of ulcerative oral mucositis in

IntraBiotics Pharmaceuticals Inc. (IBPI), Mountain View, Calif.
Product: Iseganan (formerly protegrin) oral rinse

Read the full 133 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers